New hope for kids with tough cancers: targeted drug trial launches

NCT ID NCT07584499

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while also checking if it helps shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor diffuse intrinsic pontine glioma head and neck squamous cell carcinoma medulloblastoma nasopharyngeal carcinoma nasopharyngeal type undifferentiated carcinoma Neoplasm Metastasis neuroblastoma Recurrence rhabdoid tumor rhabdomyosarcoma Squamous Cell Carcinoma of Head and Neck Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL TERATOID/RHABDOID TUMORS DIFFUSE INTRINSIC PONTINE GLIOMAS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) LYMPHOEPITHELIAL CARCINOMA MEDULLOBLASTOMA NASOPHARYNGEAL CARCINOMA NEUROBLASTOMA OTHER EGFR-POSITIVE PEDIATRIC SOLID TUMORS DEEMED ELIGIBLE BY THE INVESTIGATOR RHABDOMYOSARCOMA WILMS TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.